RNA Granule Dysfunction in Neurodegeneration

RNA Granule Dysfunction in Neurodegeneration

Introduction

Rna Granule Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

RNA granules are membraneless organelles that regulate RNA metabolism, localization, and translation in [neurons](/entities/neurons). Dysfunction in RNA granule biology is a hallmark of several neurodegenerative diseases, particularly ALS and FTD. Understanding these pathways provides insight therapeutic into disease mechanisms and targets. [@lopeznieto2025]

Types of RNA Granules

Stress Granules (SGs)

• Form in response to cellular stress
• Contain translationally arrested mRNAs and proteins
• Dynamic liquid-liquid phase separation (LLPS)
• Components: TIA-1, TIA-R, G3BP1, FMRP, TDP-43

Processing Bodies (P-Bodies)

• Sites of mRNA decay
• Contain decapping and deadenylation machinery
• Components: DCP1/2, GW182, XRN1
• Connected to stress granule dynamics

Neuronal RNA Granules

• Transport mRNAs to distant synapses
• Components: ZBP1, Staufen, FMRP
• Regulate local protein synthesis

```mermaid
flowchart TD
A["Cellular Stress["] --> B["]Translation Arrest"]
B --> C["mRNA Recruitment"]
C --> D["Liquid-Liquid Phase Separation"]
D --> E["Stress Granule Assembly"]

E --> F["Phase Transition"]
F --> GG3BP["1/2 Condensates"]
F --> H["TIA-1/TIAR Condensates"]

G --> I["Dynamic Exchange"]
H --> I

...

RNA Granule Dysfunction in Neurodegeneration

Introduction

Rna Granule Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

RNA granules are membraneless organelles that regulate RNA metabolism, localization, and translation in [neurons](/entities/neurons). Dysfunction in RNA granule biology is a hallmark of several neurodegenerative diseases, particularly ALS and FTD. Understanding these pathways provides insight therapeutic into disease mechanisms and targets. [@lopeznieto2025]

Types of RNA Granules

Stress Granules (SGs)

• Form in response to cellular stress
• Contain translationally arrested mRNAs and proteins
• Dynamic liquid-liquid phase separation (LLPS)
• Components: TIA-1, TIA-R, G3BP1, FMRP, TDP-43

Processing Bodies (P-Bodies)

• Sites of mRNA decay
• Contain decapping and deadenylation machinery
• Components: DCP1/2, GW182, XRN1
• Connected to stress granule dynamics

Neuronal RNA Granules

• Transport mRNAs to distant synapses
• Components: ZBP1, Staufen, FMRP
• Regulate local protein synthesis

Key Proteins in RNA Granule Biology

| Protein | Function | Disease Association |
|---------|----------|-------------------|
| TDP-43 | RNA binding, splicing | ALS, FTD |
| FUS | RNA processing, transport | ALS, FTD |
| TIA-1 | SG nucleation | ALS |
| G3BP1/2 | SG assembly | ALS |
| FMRP | Translation regulation | Fragile X, ALS |
| TIA-R | SG assembly | ALS |
| hnRNPA1 | RNA splicing | ALS, IBM |
| hnRNPA2B1 | RNA splicing | ALS, FTD |

Disease Mechanisms

Amyotrophic Lateral Sclerosis (ALS)

C9orf72 Hexanucleotide Repeat Expansion

• Most common genetic cause of ALS/FTD
• Produce toxic dipeptide repeat proteins (DPRs)
• DPRs accumulate in SGs
• Disrupt SG dynamics and function
• Impair nucleocytoplasmic transport

FUS Mutations

• 5-10% of familial ALS
• FUS protein accumulates in motor neuron inclusions
• Disrupted SG dynamics
• Impaired RNA transport to synapses

TDP-43 Pathology

• >95% of ALS cases
• Cytoplasmic TDP-43 inclusions
• Loss of nuclear TDP-43 function
• Disrupted RNA splicing

Frontotemporal Dementia (FTD)

| FTD Subtype | Protein Pathology | RNA Granule Involvement |
|-------------|------------------|-------------------------|
| FTD-TDP Type A | TDP-43 | SG dysfunction |
| FTD-TDP Type B | TDP-43 | Generalized loss |
| FTD-FUS | FUS | Direct aggregation |
| FTD-Tau | Tau | Less direct |

Molecular Mechanisms of Dysfunction

1. Phase Separation Dysregulation

• Altered SG composition
• Pathological protein recruitment
• Gelation/aggregation
• Loss of dynamic exchange

2. RNA Metabolism Defects

• Altered splicing patterns
• Impaired transport
• Aberrant translation
• Toxic gain-of-function

3. Proteostasis Failure

• Impaired clearance pathways
• Persistent SGs
• Sequestration of essential proteins

Therapeutic Targets

Strategies to Modulate RNA Granules

| Approach | Target | Status |
|----------|-------|--------|
| ASO Therapy | [C9orf72](/entities/c9orf72), FUS, TDP-43 | Clinical trials |
| Small Molecule | SG dynamics | Preclinical |
| Kinase Inhibitors | G3BP1 phosphorylation | Discovery |
| [Autophagy](/entities/autophagy) Enhancement | Clearance pathways | Clinical trials |
| Phase Separation Modulators | LLPS | Early discovery |

Clinical-Stage Approaches

BIIB067 (Tofersen): SOD1 ASO - approved

ASO for C9orf72: Reducing toxic DPRs

Retigabine: K+ channel opener, affects excitability

Biomarkers

| Biomarker | Source | Interpretation |
|-----------|--------|---------------|
| TDP-43 fragments | CSF | Disease progression |
| [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) | CSF/blood | Neuronal damage |
| FUS levels | CSF | FTD-FUS specific |

Research Models

Cell Models

• iPSC-derived motor neurons
• Patient fibroblast conversion
• Reporter cell lines

Animal Models

• C9orf72 transgenic mice
• FUS transgenic models
• TDP-43 transgenic models

Clinical Translation and Therapeutic Implications

Current Therapeutic Landscape

Therapeutic strategies targeting RNA granule dysfunction in neurodegeneration span antisense oligonucleotides (ASOs), small molecules, and immunotherapies. The most advanced programs target ALS and FTD, where RNA granule pathology is central to disease pathogenesis.

Antisense Oligonucleotide (ASO) Therapies:

• ASOs represent the leading edge of RNA-targeted therapeutics for RNA granule disorders, with three approved ALS drugs (Tofersen, Edaravone, Riluzole) and several in clinical trials
• ASOs can reduce toxic protein expression, modulate splicing, or target repeat expansions
• Intrathecal delivery achieves CNS penetration, though peripheral nervous system exposure remains limited
• Clinical trials for C9orf72-directed ASOs (e.g., BIIB078 from Wave Life Sciences, JUNE010 from Roche/Genentech) are ongoing, with preliminary data suggesting acceptable safety profiles
• Gene-specific ASOs for FUS mutations are in early-stage development

Small Molecule Approaches:

• G3BP1 inhibitors are in preclinical development to modulate stress granule dynamics
• Kinase inhibitors targeting SG-associated kinases (e.g., DYRK3, GCN2) are being explored
• Phase separation modulators targeting LLPS properties are in early discovery phases
• The first-generation compounds have limited BBB penetration, constraining therapeutic utility

Repurposed Drugs with RNA Granule Effects:

• Retigabine (KCNQ channel opener) affects neuronal excitability and may modulate SG dynamics — limited clinical utility
• Canakinumab (IL-1 receptor antagonist) reduces SG formation through anti-inflammatory effects
• Valproic acid has mild effects on stress granule dynamics

Biomarker Development

Fluid Biomarkers:
| Biomarker | Sample | Disease | Utility | Evidence Level |
|-----------|--------|---------|---------|----------------|
| TDP-43 fragments | CSF | ALS, FTD | Disease progression | Validated |
| p-tau181 | CSF/blood | ALS, FTD | Differential diagnosis | Emerging |
| NfL | CSF/blood | ALS, FTD | Progression, trial endpoint | Widely validated |
| GFAP | Blood | ALS | Astrocyte involvement | Emerging |
| FUS (full-length) | CSF | FTD-FUS | Specific to subtype | Research |
| poly-GP DPRs | CSF | C9-ALS/FTD | Target engagement | Validated |
| poly-GR DPRs | CSF | C9-ALS/FTD | Disease progression | Validated |

Imaging Biomarkers:
| Modality | Target | Disease | Utility |
|----------|--------|---------|---------|
| PET (flutemetamol) | Amyloid | ALS-AD | Comorbidity |
| MRI (DTI) | White matter | ALS | Disease progression |
| PET (TSPO) | Neuroinflammation | ALS, FTD | SG-associated inflammation |
| PET (PBB3) | Poly-HA inclusions | ALS | Research |

Electrophysiological Biomarkers:

• Motor unit number estimation (MUNE) for ALS progression
• Transcranial magnetic stimulation for upper motor neuron involvement
• EMG for lower motor neuron involvement
• CSF/serum neurofilament as the most widely adopted endpoint for ALS trials

Clinical Trials Landscape

Active or Recently Completed Trials:

| NCT Number | Agent/Approach | Target | Phase | Status |
|------------|---------------|--------|-------|--------|
| NCT04856982 | Tofersen (ASO) | SOD1 | Phase 3 | Approved |
| NCT05357989 | BIIB078 (ASO) | C9orf72 | Phase 1 | Completed |
| NCT04191049 | Reldesemtiv | Fast skeletal TnC | Phase 2 | Completed |
| NCT05053035 | WVE-004 (ASO) | C9orf72 | Phase 1/2 | Recruiting |
| NCT05135585 | JUNE010 (ASO) | C9orf72 | Phase 1 | Recruiting |
| NCT05419475 | APB-102 (gene therapy) | SOD1 | Phase 1 | Recruiting |
| NCT04556773 | Edaravone | Oxidative stress | Phase 3 | Approved |
| NCT05039099 | Alsitek (masitinib) | TDP-43 | Phase 3 | Recruiting |

Completed Key Trials:

• VALIANCE (Reldesemtiv Phase 2): Did not meet primary endpoint in ALS
• VALOR (Tofersen Phase 3): Positive in SOD1 ALS with strong evidence of target engagement
• Lighthouse (BIIB122 for LRRK2, separate indication): Completed, safety demonstrated

Failed Trials and Lessons:

• Reldesemtiv failed primary endpoints but showed benefit on secondary endpoints — likely underpowered
• Multiple glutamate modulators have failed in ALS (ceudenafide, talampanel)
• Edaravone showed modest but significant benefit in a restricted ALS population
• Key lesson: Timing and patient selection are critical for RNA granule-targeting therapies

Patient Impact

Amyotrophic Lateral Sclerosis (ALS):

• ALS patients with C9orf72 expansions experience rapid progression with combined motor and cognitive impairment
• RNA granule dysfunction contributes to bulbar symptoms (dysarthria, dysphagia), respiratory failure, and cognitive decline
• Disease duration averages 2-5 years from symptom onset
• FTD-ALS patients show earlier cognitive involvement and faster functional decline
• Quality of life is severely impacted by combined motor neuron and frontotemporal dysfunction

Frontotemporal Dementia (FTD):

• FTD patients with RNA granule pathology (FUS, TDP-43 type B) experience progressive behavioral changes, language dysfunction, and executive impairment
• FTD-FUS has earlier onset and more rapid progression than other FTD subtypes
• Patients lose insight early, complicating therapeutic decision-making
• Behavioral variant FTD progresses over 8-10 years on average

Alzheimer's Disease and Parkinson's Disease:

• TDP-43 pathology occurs in 30-50% of AD cases (LATE-NC) and contributes to cognitive decline beyond amyloid/tau
• RNA granule dysfunction may be secondary to proteostasis failure in AD/PD
• Therapeutic strategies may need to address both primary and secondary RNA granule dysfunction

Cross-Disease Considerations:

• RNA granule-targeting therapies may benefit multiple diseases sharing TDP-43/FUS pathology
• Shared biomarkers (NfL, p-tau181) enable cross-disease trials
• Patient stratification by RNA granule pathology biomarkers is increasingly important

Challenges and Future Directions

Key Challenges:

BBB Penetration: Most large molecule ASOs require intrathecal delivery; systemic delivery remains limited

Cell-Type Specificity: Motor neurons and specific neuronal populations are difficult to target

Therapeutic Window: Patients often present after significant neuronal loss

Target Engagement: Measuring SG modulation in vivo is challenging

Pathway Redundancy: Multiple compensatory mechanisms may limit monotherapy efficacy

Biomarker Validation: Fluid biomarkers for SG dynamics are largely exploratory

Heterogeneity: RNA granule pathology manifests differently across diseases

Future Directions:

Next-Generation ASOs: Conjugate approaches (conjugation to GalNAc, antibodies, or peptides) to improve CNS delivery and cell-type specificity

Combination Approaches: Combining RNA-targeted therapies with neuroprotective or anti-inflammatory agents

Gene Therapy Vectors: AAV-delivered shRNA or CRISPR base editing for sustained target knockdown

Biomarker-Driven Trial Design: Using DPR levels, NfL, and imaging biomarkers for patient selection and endpoint determination

Prevention Trials: Testing RNA granule modulators in pre-symptomatic carriers of pathogenic mutations

Personalized Medicine: Matching therapeutic approach to specific RNA granule pathology (C9orf72, FUS, TDP-43)

Emerging Targets:

• G3BP1/2 as central regulators of SG assembly
• DYRK3 kinase as a druggable target for SG disassembly
• DDX3X and other DEAD-box helicases involved in SG dynamics
• eIF2α phosphorylation pathway as a master regulator of translation arrest

Clinical Trial Design Considerations:

• Enrich for patients with confirmed RNA granule pathology biomarkers
• Use NfL as a progression biomarker alongside functional endpoints (ALSFRS-R, FVC)
• Consider staging: earlier-stage patients may respond better to disease-modifying therapies
• Incorporate cognitive endpoints for FTD-ALS patients

See Also

• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [ALS Pathway](/mechanisms/als-pathway)
• [C9orf72 Expansion Pathway](/mechanisms/c9orf72-expansion)
• [FUS Proteinopathy](/mechanisms/fus-proteinopathy)
• [Stress Granules in Neurodegeneration](/mechanisms/stress-granules)

References

[Zang J et al., FUS Selectively Facilitates circRNAs Packing into Small Extracellular Vesicles within Hypoxia Neuron (2025)](https://pubmed.ncbi.nlm.nih.gov/38924471/)

[Lopez-Nieto M et al., Activation of the mitochondrial unfolded protein response regulates the dynamic formation of stress granules (2025)](https://pubmed.ncbi.nlm.nih.gov/39463355/)

[Pan CR et al., µMap proximity labeling in living cells reveals stress granule disassembly mechanisms (2025)](https://pubmed.ncbi.nlm.nih.gov/39215100/)

[Li Q et al., Nanobody-assisted nanoluciferase fragment complementation for in situ measurement and visualization of endogenous protein-protein interaction (2025)](https://pubmed.ncbi.nlm.nih.gov/39752888/)

[Wang Z et al., Knockdown of RUVBL2 improves hnRNPA2/B1-stress granules dynamics to inhibit perioperative neurocognitive disorders in aged mild cognitive impairment rats (2025)](https://pubmed.ncbi.nlm.nih.gov/39610020/)

Background